Daniel Fady, Cadranel Jean-François, Seksik Philippe, Cazier Alain, Duong Van Huyen Jean-Paul, Ziol Marianne, Coutarel Pierre, Loison Patrick, Jian Raymond, Marteau Philippe
Département d'Hépato-Gastroentérologie, Hôpital Européen Georges Pompidou, AP-HP, Paris.
Gastroenterol Clin Biol. 2005 May;29(5):600-3. doi: 10.1016/s0399-8320(05)82136-0.
Purine analogues are major drugs in the treatment of inflammatory bowel diseases (IBD). We present four cases of nodular regenerative hyperplasia of the liver (NRH) developed in patients with IBD treated with azathioprine. All patients had either abnormal liver tests and/or low platelet count. Although biochemical and hematological abnormalities regressed after azathioprine withdrawal, the long term evolution of the hepatic lesions (and the risk to develop further complications including portal hypertension) remains to be determined. Male gender seems to be a major risk factor by providing a predisposing pharmacogenetic profile of purine analogue metabolism. Clinicians should be aware of this serious complication which may occur with any of the purine analogues (azathioprine, 6-mercaptopurine, and 6-thioguanine).
嘌呤类似物是治疗炎症性肠病(IBD)的主要药物。我们报告了4例接受硫唑嘌呤治疗的IBD患者发生肝结节性再生性增生(NRH)的病例。所有患者均有肝功能检查异常和/或血小板计数低的情况。尽管停用硫唑嘌呤后生化和血液学异常有所缓解,但肝脏病变的长期演变(以及发生包括门静脉高压在内的进一步并发症的风险)仍有待确定。男性似乎是一个主要危险因素,因为其具有嘌呤类似物代谢的易患药物遗传学特征。临床医生应意识到这种严重并发症可能发生在任何一种嘌呤类似物(硫唑嘌呤、6-巯基嘌呤和6-硫鸟嘌呤)治疗过程中。